Chairman of the Board of Directors of Biogen Inc., Exelixis, Inc., and Regulus Therapeutics, Inc. He is a co-founder of Exelixis, as well as co-founder and former Chairman of Anadys Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and Cellzome (acquired by GlaxoSmithKline in 2012). In the not-for-profit sector, Dr. Papadopoulos is a member of the Board of Visitors of Duke Medicine, a member of the Global Advisory Board of the Duke Institute for Health Innovation, and co-founder and Chairman of Fondation Santé (www.fondationsante.org), a foundation providing research support and mentorship to biomedical scientists in Greece and Cyprus.
Dr. Stelios Papadopoulos spent six years (2000-06) at Cowen & Co., LLC, most recently as Vice Chairman, where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where he was an analyst in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette. Dr. Papadopoulos has received multiple honors and awards for his work in the biopharma industry as a company founder, adviser, and financier.
Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University School of Medicine. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an M.B.A. in finance, all from New York University.